No phaseCompleted
Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels
Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels: A Double-Blind Parallel Trial
- Sponsor
- Qualia Life Sciences (Industry)
- Enrolment
- 72 enrolled
- Conditions
- Magnesium Deficiency
- Interventions
- Qualia Magnesium+®; Placebo
- Ages
- adults, older adults
- Registry
- NCT06979648
Full record on ClinicalTrials.gov
From the registry
This is a double-blind, placebo-controlled parallel trial designed to evaluate the effectiveness of Qualia Magnesium+® supplementation on red blood cell (RBC) magnesium levels in adults aged 21 and older. Approximately 100 participants with baseline RBC magnesium levels below 6.0 mg/dL will be assigned using systematic allocation to receive either Qualia Magnesium+ or a placebo. Participants will take 2 capsules daily in the evening, with or without food, for a duration of 12 weeks. The primary outcome is the between-group change in RBC magnesium levels from baseline to Week 12. Secondary outcomes include assessments of sleep quality, perceived stress, magnesium status, and safety and tolerability. Data collection will occur through lab bloodwork and electronic questionnaires.
Primary outcomes
- Between-group change in RBC magnesium levels
History
Last registry update
Study completion
Primary completion
Started
Registered